

BIOPSYBELL	PREMARKET NOTIFICATION SUBMISSION – 510 (k)	Data: 04-10-2001
	OSTEOBELL™	Pag. 28 di 28

K011104

MAY 31 2001

## 510 (k) SUMMARY

- **Applicant** : Biopsybell s.a.s.  
Via Lea Cazzuoli 14/16 – S.Giacomo Roncole (MO) Italy
- **Contact Person** : MMC International, LLC  
Mr. Lucio Improta  
131 Highwood Drive – S. Glastonbury, CT 06073  
Tel. (860) 633-8807 – fax. (860) 657-8913  
e-mail : mmcintern@aol.com
- **Submission Date** : April 10, 2001
- **Trade Name** : Osteobell™ Bone Marrow Biopsy Needle
- **Common Name** : Bone Marrow Biopsy Needle
- **Classification Name** : 876.1075 - Biopsy instrument

### ❖ Indication for use :

*This biopsy instrument is used for drawing of osteomedullary substance and or for explantation of bone marrow*



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 31 2001

Biopsybell, S.A.S.  
c/o Mr. Lucio Improta  
MMC International, L.L.C.  
131 Highwood Drive  
South Glastonbury, Connecticut 06073

Re: K011104  
Trade/Device Name: Osteobell™ Biopsy Needle  
Regulation Number: 876.1075  
Regulatory Class: II  
Product Code: KNW  
Dated: April 10, 2001  
Received: April 11, 2001

Dear Mr. Improta:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

for Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative  
and Neurological Devices

Office of Device Evaluation

Center for Devices and  
Radiological Health

Enclosure

BIOPSYBELL	PREMARKET NOTIFICATION SUBMISSION – 510 (k)	Data: 04-10-2001  Pag. 11 di 28
	OSTEOBELL™	

510 (k) # 011104

DEVICE NAME

Osteobell™ Biopsy Needle


**INDICATION FOR USE**

This biopsy instrument is used for drawing of osteomedullary substance and or for explantation of bone marrow

PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED

-----

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
 (Division Sign-Off)  
 Division of General, Restorative  
 and Neurological Devices

510(k) Number K011104

Prescription Use ✓  
 (Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_